The Food and Drug Administration on Wednesday issued an emergency use authorization for the Novavax Covid-19 vaccine, giving Americans over the age of 18 a fourth vaccine selection as the United States prepares to expand inoculations as the BA. 5 omicron subprogeny spreads.
Novavax’s vaccine program consists of two doses 3 weeks apart and includes a small Covid-19 “spike protein” that teaches the immune formula to recognize and fight long-lasting infections used in shingles and hepatitis B vaccines.
Trials show that the vaccine is 90. 4% effective in preventing mild, moderate or severe COVID-19 infections, and no moderate or severe COVID-19 cases have been reported in the 17,200 participants who won the vaccine.
Officials hope the protein-based Novavax vaccine will be a good choice for Americans who are resistant or unable to obtain vaccines made through Pfizer-BioNTech and Moderna, which use a new generation of mRNA (about one in five Americans have won a first COVID-19 vaccine). vaccine, according to the Centers for Disease Control and Prevention).
The Novavax vaccine has already been approved for use and administered in dozens of countries and the European Union. Biden’s management announced Monday that it has received 3. 2 million doses of Novavax for national distribution with FDA approval. Progressing over two years, the vaccine plagiarized through production problems. Last week, the CDC announced that the new subvariant omicron BA. 5 is the dominant form of Covid-19 circulating in the United States and leads to a buildup of new infections and hospitalizations.
USA. U. S. Gets 3. 2 Million Novavax Covid Vaccines: Offers An Alternative to mRNA Injections as New Variants Spread (Forbes)
The highly contagious BA. 5 variant becomes dominant in the U. S. U. S. Covid cases (Forbes)
Full Coronavirus Policy and Updates